Источники - взаимодействия между рекреационными наркотиками и антиретровирусными препаратами
| Оглавление |
|---|
| Взаимодействия между рекреационными наркотиками и антиретровирусными препаратами |
| Источники |
References
1. Palella FJJ,Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten
GA, et al. Decliningmorbidity and mortality among patients with advanced
humanimmunodeficiency virus infection. HIV Outpatient Study
Investigators. N EnglJ Med 1998-338:853-60.
2. Cameron DW,Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath
C, et al. Randomisedplacebo-controlled trial of ritonavir in advanced
HIV-1 disease. TheAdvance HIV Disease Ritonavir Study
Group. Lancet1998-351:543-9.
3. Hammer SM, SquiresKE, Hughes MD, Grimes JM, Demeter LM, Currier
JS, et al. Acontrolled trial of two nucleoside analogues plus indinavir
in persons with humanimmunodeficiency virus infection and CD4 cell
counts of 200 percubic millimeter or less. AIDS Clinical Trials Group
320 Study Team. NEngl J Med 1997-337:725-33.
4. Van Cleef G,Fisher EJ, Polk RE. Drug interaction potential with inhibitors
of HIV protease.Pharmacotherapy 1997-17:774-8.
5.Preston SL, Postelnick M, Purdy BD, Petrolati J, Aasi H, Stein DS. Drug
interactions inHIV-positive patients initiated on protease inhibitor therapy
(letter). AIDS1998-12:228-30.
6. von Moltke LL,Greenblatt DY, Grassi JM, Granda BW, Duan SX, Fogelman
SM, et al. Proteaseinhibitors as inhibitors of human cytochromes
P450: high riskassociated with ritonavir. J Clin Pharmacol 1998-38:106;
11.
7. von Moltke LL,Greenblatt DJ, Granda BW, Giancarlo GM, Duan SX,
Daily JP, et al.Inhibition of cytochrome P450 isoforms by nonnucleoside
reverse transcriptaseinhibitors. J Clin Pharmacol 2001-41:85-91.
8. Deeks SG, Smith M,Holodniy M, Kahn JO. HIV-1 protease inhibitors: a
review forclinicians. JAMA 1997-277:145-53.
9. Barry M, GibbonsS, Back D, Mulcahy F. Protease inhibitors in patients
with HIV disease.Clinically important pharmacokinetic considerations.
Clin Pharmacokinet1997-32:194-209.
10. Piscitelli SC,Flexner C, Minor JR, Polis MA, Masur H. Drug interactions
in patients infectedwith HIV. Clin Infect Dis 1996-23:685-93.
11. Barry M, MulcahyF, Merry C, Gibbons S, Back D. Pharmacokinetics
and potentialinteractions amongst antiretroviral agents used to treat patients
with HIV infection.Clin Pharmacokinet 1999-36:289-304.
12. Tseng AL, FoisyMM. Management of drug interactions in patients with
HIV. Ann Pharmacother1997-31:1040-58.
13. Productmonograph. Sustiva (efavirenz).Princeton,NJ:Bristol Myers
Squibb Pharma,February 2002.
14. Patrick DM,Strathdee SA, Currie S, Pitchford W, Rekart ML, FitzGerald
M, et al. Incidenceof HIV in theVancouverIDU Study Cohort. Presented
at: 6th AnnualCanadian Conference on HIV/AIDS Research,Ottawa,
May 22–26, 1997.
15. Clarke S, Quah S,Courtney G,LyonsF, Bergin C, Mulcahy F. A rapidly
increasing incidenceof HIV infection in injecting drug users (IDU) in
Ireland(abstract). Presented at: 8th Conferenceon Retroviruses and Opportunistic
Infections,Chicago,February 4–8, 2001.
16. HIV/AIDSsurveillance report.Atlanta:Centers for Disease Control and
Prevention,2001-13:1- 41.
17. Geduld J,Archibald C. National trends of HIV and AIDS inCanada.
CanadaCommun Dis Rep 2000-26:193-201.
18. Henry JA, HillIR. Fatal interaction between ritonavir and MDMA.
Lancet 1998-352:1751-2.
19. Bertz RJ, GrannemanGR. Use of in vitro andin vivo data to estimate the
likelihood ofmetabolic pharmacokinetic interactions. Clin Pharmacokinet
1997-32:210-58.
20. Jacobs MR,O’Brien Fehr K. Drugs and drug abuse: a reference text.
Toronto: Alcoholism and Drug Addiction ResearchFoundation, 1987.
21. Tucker GT,Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, et al.
The demethylenationof methylenedioxymethamphetamine (“ecstasy”)
by debrisoquinehydroxylase (CYP2D6). Biochem Pharmacol 1994-47:
1151-6.
22. Colado MI,Williams JL,GreenAR. The hyperthermic and neurotoxic
effects of ‘Ecstasy’(MDMA) and 3,4 methylenedioxyamphetamine
(MDA) in the DarkAgouti (DA) rat, a model of the CYP2D6 poor metabolizer
phenotype. Br JPharmacol 1995-115:1281-9.
23. Kreth K, Kovar K,Schwab M, Zangar UM. Identification of the human
cytochromes P450involved in the oxidative metabolism of “Ecstasy”-related
drugs. BiochemPharmacol 2000-15:1563-71.
24. Sherlock K, WolffK, Hay AW, Conner M. Analysis of illicit ecstasy
tablets: implicationsfor clinical management in the accident and emergency
department. J AccidEmerg Med 1999-16:194-7.
25. Hesse LM, von MoltkeLL, Shader RI, Greenblatt DJ. Ritonavir,
efavirenz, andnelfinavir inhibit CYP2B6 activity in vitro: potential drug
interactions withbupropion. Drug Metab Dispos 2001-29:100-2.
26. Lin LY, Kumagai Y,Hiratsuka A, Narimatsu S, Suzuki T, Funae Y, et al.
Cytochrome P4502Disozymes catalyze the 4-hydroxylation of methamphetamine
enantiomers. DrugMetab Dispos 1995-23:610-4.
27. Geertsen S,FosterBC,Wilson DL, Cyr TD, Casley W. Metabolism of
methoxyphenamine and2-methoxyamphetamine in P4502D6-transfected
cells and cellpreparations. Xenobiotica 1995-25:895-906.
28. Lin LY, DiStefano EW, Schmitz DA, Hsu L, Ellis SW, Lennard MS, et
al. Oxidation ofmethamphetamine and methylenedioxymethamphetamine
by CYP2D6. Drug MetabDispos 1997-25:1059-64.
29. Lettieri JT, FungHL. Dose-dependent pharmacokinetics and hypnotic
effects of sodiumgamma-hydroxybutyrate in the rat. J Pharmacol Exp
Ther 1979-208:7-11.
30. Lettieri JT, FungHL. Absorption and first pass metabolism of 14C-gamma;
hydroxybutyric acid.Res Commun Chem Pathol Pharmacol 1976;
13:425-37.
31. Harrington RD,Woodward JA, Hooton TM, Horn JR. Life-threatening
interactions betweenHIV-1 protease inhibitors and the illicit drugs
MDMA andgamma-hydroxybutyrate. Arch Intern Med 1999-159:2221;
4.
32. White PF, Way WL,Trevor AJ. Ketamine — its pharmacology and therapeutic
uses. Anesthesiology1982-56:119-36.
33. Yanagihara Y,Kariya S, Ohtani M, Uchino K, Aoyama T, Yamamura Y,
et al. Involvement ofCYP2B6 in n-demethylation of ketamine in human
liver microsomes. DrugMetab Dispos 2001-29:887-90.
34. Loch JM, Potter J,Bachman KA. The influence ofanesthetic agents on
rat hepatic cytochromesP450 in vivo. Pharmacology 1995-50:146-53.
35. Menuguz A,Fortuna S, Lorenzini P, Volpe MT. Influence of urethane
and ketamine on rathepatic cytochrome P450 in vivo. Exp Toxicol
Pathol 1999-51:392-6.
36. Laurenzana EM,Owens SM. Metabolism of phencyclidine by human
liver microsomes. DrugMetab Dispos 1997-25:557-63.
37. Shelnutt SR, BadgerTM, Owens SM. Phencyclidinemetabolite irreversible
binding in the rat:gonadal steroid regulation and CYP2C11. J
Pharmacol Exp Ther1996-277:292-8.
38. Crowley JR,Hollenberg PF. Mechanism-based inactivation of rat liver
cytochrome P4502B1 byphencyclidine and its oxidative product, the
iminium ion. Drug MetabDispos 1995-23:786-93.
39. Inoue T,Niwaguchi T, Murata T. Effects of inducers and/or inhibitors on
metabolism oflysergic acid diethylamide in rat liver microsomes. Xenobiotica
1980-10:913-20.
40. Cai J, Henion J.Elucidation of LSD in vitro metabolism by liquid chromatography
and capillaryelectrophoresis coupled with tandem mass
spectrometry. J AnalToxicol 1996-20:27-37.
41. Iribarne C,Berthou F, Baird S, Dreano Y, Picart D, Bail JP, et al. Involvement
of cytochrome P4503A4 enzyme in the N-demethylation of
methadone in humanliver microsomes. Chem Res Toxicol 1996-9:365;
73.
1610 The Annals ofPharmacotherapy 2002 October, Volume36 theannals.com
T Antoniou and AL Tseng
42. Foster DJ,Somogyi AA, Bochner F. Methadone N-demethylation in human
liver microsomes:lack of stereoselectivity and involvement of
CYP3A4. Br J ClinPharmacol 1999-47:403-12.
43. Eap CB, Broly F,Mino A, Hammig R, Deglon JJ, Uehlinger C, et al.Cytochrome
P450 2D6 genotype andmethadone steady-state concentrations.
J ClinPsychopharmacol 2001-21:229-34.
44. Gerber JG, RhodesRJ. Cytochrome P450 2B6 metabolizes methadone
preferentially andstereospecifically. An explanation of drug interaction
with antiretroviraldrugs (abstract 2.2). Presented at: First International
Workshop on ClinicalPharmacology of HIV Therapy, Noordwijk, the
Netherlands,March 30–31, 2000:14.
45. Clarke SM,Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG,
et al. Thepharmacokinetics of methadone in HIV-positive patients receiving
the non-nucleosidereverse transcriptase inhibitor efavirenz. Br J
Clin Pharmacol2001-51:213-7.
46. Heelon MW, Meade LB. Methadone withdrawalwhen starting an
antiretroviralregimen including nevirapine. Pharmacotherapy 1999-19:471;
2.
47. Marzolini C,Troillet N, Telenti A, Baumann P, Decosterd LA, Eap CB.
Efavirenz decreasesmethadone blood concentrations. AIDS 2000-14:1291;
2.
48. Pinzani V,Faucherre V, Peyriere H, Blayac JP. Methadone withdrawal
symptoms withnevirapine and efavirenz (letter). Ann Pharmacother
2000-34:405-7.
49. Staszewski S,Haberl A, Gute P, Nisius G, Miller V, Carlebach A.
Nevirapine/didanosine/lamivudineonce daily in HIV-1 infected intravenous
drug users. AntiviralTher 1998-3:55-6.
50. Altice FL,Friedland GH, CooneyE. Nevirapine inducedopiate withdrawal
among injection drugusers with HIV infection receiving
methadone. AIDS1999-13:957-62.
51. Otero MJ, FuertesA, Sanchez R, Luna G. Nevirapine-induced withdrawal
symptoms in HIVpatients on methadone maintenance programme:
an alert. AIDS1999-13:1004-5.
52. Geletko SM,Erickson AD. Decreased methadone effect after ritonavir
initiation.Pharmacotherapy 2000-20:93-4.
53. Hsyu PH,Lillibridge JH, Maroldo L, Weiss WR, Kerr BM. Pharmacokinetic
and pharmacodynamicinteractions between nelfinavir and methadone
(abstract 87).Presented at: 7th Conference on Retroviruses and Opportunistic
Infections,San Francisco, January30–February 2, 2000.
54. Gerber JG,Rosenkranz S, Segal Y, Aberg J, D’Amico R, Mildvan D, et
al. The effect ofritonavir/saquinavir on the stereoselective pharmacokinetics
of methadone: resultsof AIDS clinical trials group (ACTG) 401. J
Acq Immune Def Synd2001-27:153-60.
55. Hendrix C, WakefordJ, Wire MB, Bigelow G, Cornell E, Christopher J,
et al.Pharmacokinetic and pharmacodynamic evaluation of methadone
enantiomers followingco-administration with amprenavir in opioid-dependent
subjects (abstract1649). Presented at: 40th Interscience Conference
on AntimicrobialAgents and Chemotherapy,Toronto,September
17–20, 2000:335.
56. Maroldo L,Manocchio S, Artenstein A, Weiss W. Lack of effect of nelfinavir
mesylate onmaintenance methadone dose requirement (abstract
WePeB4120). Presentedat: XIII International AIDS Conference,Durban,
South Africa,July 9–14, 2000:60.
57. McCance-Katz EF,Farber S, Selwyn PA, O’Connor A. Decrease in
methadone levels withnelfinavir mesylate (letter). Am J Psychiatry
2000-157:481.
58. Beauverie P,Taburet AM, Dessalles MC, Furlan V, Touzeau D. Therapeutic
drug monitoring ofmethadone in HIV-infected patients receiving
protease inhibitors.AIDS 1998-12:2510-1.
59. Rainey PM,Friedland G, McCance-Katz EF, Andrews L, Mitchell SM,
Charles C, et al.Interaction of methadone with didanosine and stavudine.
J Acq Immune Def Synd2000-24:241-8.
60. Schwartz EL,Brechbuhl AB, Kahl P, Miller MA, Selwyn PA, Friedland
GH. Pharmacokineticinteractions of zidovudine and methadone in intravenous
drug–using patientswith HIV infection. JAcq Immune Def
Synd 1992-5:619-26.
61. McCance-Katz EF,Rainey PM, Jatlow P, Friedland G. Methadone effects
on zidovudinedisposition (AIDS clinical trials group 262). J Acq
Immune Def Synd1998-18:435- 43.
62. Sellers E, Lam R,McDowell J, Corrigan B, Hedayetullah N, Somer G,
et al. Thepharmacokinetics of abacavir and methadone following coadministration:
CNAA1012 (abstract663). Presented at: 39th Interscience
Conference onAntimicrobial Agents and Chemotherapy,SanFrancisco,
September 26–28,1999:25.
63. Booker B, SmithP, Forrest A, Difrancesco R, Morse G, Cottone P, et al.
Lack of effect ofmethadone (MET) on the pharmacokinetics (PK) of
delavirdine (DLV)& N-delavirdine (abstract A 490). Presentedat: 41st
InterscienceConference on Antimicrobial Agents and Chemotherapy,
Chicago,December 16–19, 2001:14.
64. Boffito M,Rossati A, Dal Conte I, Reynolds H, Gibbons S, Back D, et
al. Opiate withdrawalsyndrome in new efavirenz recipients under
methadone maintenanceregimen (abstract). Presented at: 1st IAS Conference
on HIV Pathogenesisand Treatment,Buenos Aires,July 8–11,
2001.
65. Smith PF, BookerBM, Difrancesco R, Morse GD, Cottone PF, Murphy
MK, et al. Effect ofmethadone or LAAM on the pharmacokinetics of
nelfinavir & M8(abstract A- 491). Presented at: 41st Interscience Conference
on AntimicrobialAgents and Chemotherapy,Chicago,December
16–19, 2001:14.
66. Brown LS,Chu M, Aug C, Dabo S. The use of nelfinavir and twonucleosides
concomitantly withmethadone is effective and well-tolerated in
HepC co-infectedpatients (abstract I-206). Presented at: 41st Interscience
Conference onAntimicrobial Agents and Chemotherapy,Chicago,
December 16–19, 2001:311.
67.Shelton MJ, Cloen D, Berenson C, Esch A,Brewer J, Hewitt R. Pharmacokinetics
(PK) of once daily(QD) saquinavir/ritonavir (SQV/RTV): effects
on unbound methadoneand -acidglycoprotein (AAG) (abstract
A-492). Presented at:41st Interscience Conference on Antimicrobial
Agents and Chemotherapy,Chicago,December 16–19, 2001:14.
68. Clarke SM,Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG,
et al.Pharmacokinetic interactions of nevirapine and methadone and
guidelines for use ofnevirapine to treat injection drug users. Clin Infect
Dis 2001-33:1595-7.
69. Cantilena L,McCrea J, Blazes D, Winchell G, Carides A, Royce C, et al.
Lack of apharmacokinetic interaction between indinavir and methadone
(abstract PI-74).Clin Pharmacol Ther 1999-65:135.
70. Clarke S, MulcahyF, Bergin C, Reynolds H, Boyle N, Barry MG, et al.
Absence of opioidwithdrawal symptoms in patients receiving methadone
and the proteaseinhibitor lopinavir–ritonavir. Clin Infect Dis 2002-34:
1143-5.
71. Munsiff AV, PatelJ. Regimens with once daily ritonavir + Fortovase are
highly effective inPI-experienced HIV-HCV co-infected patients on
methadone (abstract684). Presented at: 39th Annual Meeting of the Infectious
Diseases Society ofAmerica,San Francisco,October 25–28, 2001.
72. Friedland G,Rainey P, Jatlow P, Andrews L, Damle B, McCance-Katz
E. Pharmacokinetics(pK) of didanosine (ddI) from encapsulated enteric
coated beadformulation (EC) vs chewable tablet formulation in patients
(pts) on chronicmethadone therapy (abstract TuPeB4548). Presented at:
XIV InternationalAIDS Conference,Barcelona,July 7–12, 2002,vol
1:402-3.
73. Guibert A, FurlanV, Martino J, Taburet AM. In vitro effect of HIV protease
inhibitors onmethadone metabolism (abstract). Presented at: 37th
InterscienceConference on Antimicrobial Agents and Chemotherapy,
Toronto, September 28–October 1, 1997.
74. Hsu A, GrannemanGR, Carothers L, Dennis S, Chiu Y-L,ValdesJ, et al.
Ritonavir does notincrease methadone exposure in healthy volunteers
(abstract 342).Presented at: 5th Conference on Retroviruses and Opportunistic
Infections,Chicago,February 1–5, 1998.
75. Boulton DW,Arnaud P, DeVane CL. A single dose of methadone inhibits
cytochrome P- 4503Aactivity in healthy volunteers as assessed by
the urinary cortisolratio. Br J Clin Pharmacol 2001-51:350-4.
76. Iribarne C,Dreano Y, Bardou LG, Menez JF, Berthou F. Interaction of
methadone withsubstrates of human hepatic cytochrome P450 3A4.
Toxicology1997-117:13-23.
77. Wu D, Otton SV,Sproule BA, Busto U, Inaba T, Kalow W, et al. Inhibition
of human cytochromeP450 2D6 (CYP2D6) by methadone. Br J
Clin Pharmacol1993-35:30-4.
78. Zhang KE, Wu E,Patick AK, Kerr B, Zorbas M, Lankford A, et al. Circulating
metabolites of thehuman immunodeficiency virus protease inhibitor
nelfinavir in humans:structural identification, levels in plasma,
and antiviralactivities. Antimicrob Agents Chemother 2001-45:1086-93.
79. Edwards DJ,Svensson CK, Visco JP, Lalka D. Clinical pharmacokinetics
of pethidine. ClinPharmacokinet 1982-7:421-33.
80. Zhang J, BurnellJC, Dumaual N, Bosron WF. Binding and hydrolysis of
meperidine by humanliver carboxylesterase hCE-1. J Pharmacol Exp
Ther 1999-290:314-8.
81. Piscitelli S,Rock-Kress D, Bertz R,PauA, Davey R. The effect of ritonavir
on thepharmacokinetics of meperidine and normeperidine. Pharmacotherapy
2000-20:549-53.
Recreational Drug–Antiretroviral Agent Interactions
The Annals of Pharmacotherapy 2002 October, Volume 36 1611 theannals.com
82. Dayer P,Desmeules J, Striberni R. In vitro forecasting of drugs that
may interfere withcodeine bioactivation. Eur J Drug Metab Pharmacokinet
1992-17:115-20.
83. Poulsen L, BrosenK, Arendt-Neilsen L, Gram LF, Elbaek K, Sindrup
SH. Codeine andmorphine in extensive and poor metabolizers of
sparteine:pharmacokinetics, analgesic effect and side effects. Eur J
Clin Pharmacol1996-51:289-95.
84. Caraco Y,Tateishi T, Guengerich FP, Wood AJ. Microsomal codeine Ndemethylation:
cosegregation withcytochrome P4503A4 activity. Drug
Metab Dispos1996-24:761-4.
85. Yue QY, Sawe J.Different effects of inhibitors on the O- and Ndemethylation
of codeine in humanliver microsomes. Eur J Clin Pharmacol
1997-1997:41-7.
86. Caraco Y, Sheller J,Wood AJ. Pharmacogeneticdeterminants of
codeine induction byrifampin: the impact on codeine’s respiratory, psychomotor
and miotic effects. JPharmacol Exp Ther 1997-281:330-6.
87. Caraco Y, Sheller J,Wood AJ. Pharmacogeneticdetermination of the
effects of codeineand prediction of drug interactions. J Pharmacol Exp
Ther1996-278:1165-74.
88. Heiskanen T,Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the
pharmacokinetics andpharmacodynamics of oxycodone. Clin Pharmacol
Ther 1998-64:603-11.
89. Coffman BL, RiosGR, King CD, Tephly TR. Human UGT2B7 catalyzes
morphineglucuronidation. Drug Metab Dispos 1997-25:1-4.
90. Fromm MF,Eckhardt K, Li S, Schanzle G, Hofmann U, Mikus G, et al.
Loss of analgesiceffect of morphine due to coadministration of rifampin.
Pain 1997-72:261-7.
91. Osborne R, JoelS, Trew D, Slevin M. Analgesic activity of morphine;
6-glucuronide(letter). Lancet 1988-1:828.
92. Chaisson MA,Stoneburner RL, Hildebrandt DS,Ewing WE,Telzak
EE, Jaffe HW.Heterosexual transmission of HIV-1 associated with the
use of smokablefreebase cocaine (crack). AIDS 1991-5:1121-6.
93. Edlin BR, IrwinKL, Faruque S, McCoy CB, Word C, Serrano Y, et al.
Intersectingepidemics — crack cocaine use and HIV infection among
inner-city youngadults. Multicenter Crack Cocaine and HIV Infection
Study Team. N Engl JMed 1994-331:1422-7.
94. Nuttbrock L, RosenblumA, Magura S, McQuistion HL, Joseph H. The
association betweencocaine use and HIV/STDs among soup kitchen
attendees inNew York City. J Acq Immune Def Synd 2000-25:86-91.
95. Inaba T, StewartDJ, Kalow W. Metabolism of cocaine in man. Clin
Pharmacol Ther1978-23:547-52.
96. Cone EJ, TsadikA, Oyler J, Darwin WD. Cocaine metabolism and urinary
excretion afterdifferent routes of administration. Ther Drug Monit
1998-20:556-60.
97. Stewart DJ, InabaT, Lucassen M, Kalow W. Cocaine metabolism: cocaine
and norcocainehydrolysis by liver and serum esterases. Clin
Pharmacol Ther1979-25:464-8.
98. Leduc BW,Sinclair PR, Shuster L, Sinclair JF, Evans JE, Greenblatt
DJ. Norcocaine and N-hydroxynorcocaine formation in humanliver
microsomes: role ofcytochrome P- 450 3A4. Pharmacology 1993-46:
294-300.
99. Ladona MG,Gonzalez ML, Rane A, Peter RM, de la Torre R. Cocaine
metabolism in humanfetal and adult liver microsomes is related to cytochrome
P450 3A expression.Life Sci 2000-68:431- 43.
100. Hoffman RS, HenryGC, Howland MA, Weisman RS, Weil L, Goldfrank
LR. Associationbetween life-threatening cocaine toxicity and
plasma cholinesteraseactivity. Ann Emerg Med 1992-21:247-53.
101. Ndikum-MofforFM, Schoeb TR, Roberts SM. Liver toxicity from norcocaine
nitroxide, an N-oxidative metabolite of cocaine. JPharmacol
Exp Ther1998-284:413-9.
102. Roberts SM,Harbison RD, JamesRC. Human microsomal N-oxidative
metabolism ofcocaine. Drug Metab Dispos 1991-19:1046-51.
103. Pellinen P,Honkakoski P, Stenback F, Niemitz M, Alhava E, Pelkonen
O, et al. Cocaine N-demethylation and the metabolism-relatedhepatotoxicity
can be prevented bycytochrome P450 3A inhibitors. Eur J
Pharmacol1994-270:35- 43.
104. Lockridge O,Mottershaw-Jackson N, Eckerson HW, La Du BN. Hydrolysis
of diacetylmorphine(heroin) by human serum cholinesterase. J
Pharmacol Exp Ther1980-21:1-8.
105. Inturrisi CE, MaxMB, Foley KM, Schultz M, Shin SU, Houde RW.
The pharmacokineticsof heroin in patients with chronic pain.N EnglJ
Med 1984-310:1213-7.
106. Kamendulis LM,Brzezinski MR, Pindel EV, Bosron WF, Dean RA.
Metabolism of cocaineand heroin is catalyzed by the same human liver
carboxylesterases. JPharmacol Exp Ther 1996-279:713-7.
107. Jenkins AJ,Keenan RM, Henningfield JE, Cone EJ. Pharmacokinetics
and pharmacodynamicsof smoked heroin. J Anal Toxicol 1994-18:317;
30.
108. Busto UE.Benzodiazepines: the science and the myths. Can J Clin
Pharmacol1999-6:185-6.
109. Kronback T,Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation
of midazolam andtriazolam by human liver cytochrome P450IIIa4.
Mol Pharmacol1989-36:89-96.
110. VenkatakrishnanK, Greenblatt DJ, von Moltke LL, Shader RI. Alprazolam
is another substratefor human cytochrome P450-3A isoforms
(letter). J ClinPsychopharmacol 1998-18:256.
111. Frye R, Bertz R,Granneman GR, Qian J, Lamm J, Dennis S, et al. Effect
of ritonavir on thepharmacokinetics and pharmacodynamics of alprazolam
(abstract A59).Presented at: 37th Interscience Conference on
Antimicrobial Agentsand Chemotherapy,Toronto,September 28–October
1, 1997.
112. Greenblatt D,Moltke L, Harmatz J, Durol AL, Daily JP, Graf JA, et al.
Alprazolam–itonavirinteraction: implications for product labeling. Clin
Pharmacol Ther2000-67:335- 41.
113. Palkama VJ,Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir
on thepharmacokinetics and pharmacodynamics of oral and intravenous
midazolam. ClinPharmacol Ther 1999-66:33-9.
114. Merry C, MulcahyF, Barry M, Gibbons S, Back D. Saquinavir interaction
with midazolam:pharmacokinetic considerations when prescribing
protease inhibitorsfor patients with HIV disease (letter). AIDS 1997-11:
268-9.
115. Greenblatt DJ,von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf
JA, et al.Differential impairment of triazolam and zolpidem clearance
by ritonavir. J AcqImmune Def Synd 2000-24:129-36.
116. Greenblatt DJ,von Moltke LL, Daily JP, Harmatz JS, Shader RI. Extensive
impairment oftriazolam and alprazolam clearance by short-term
low-dose ritonavir:the clinical dilemma of concurrent inhibition and
induction. J ClinPsychopharmacol 1999-19:293-6.
117. Seree EJ, PisanoPJ, Placidi M, Rahmani R, Barra YA. Identification of
the human and animalhepatic cytochromes P450 involved in clonazepam
metabolism. FundamClin Pharmacol 1993-7:69-75.
118. Hesse LM,Venkatakrishnan K, von Moltke LL, Shader RI, Greenblatt
DJ. CYP3A4 is themajor CYP isoform mediating the in vitro hydroxylation
and demethylation offlunitrazepam. Drug Metab Dispos 2001-29:
133- 40.
119. Ono S, HatanakaT, Miyazawa S, Tsutsui M, Aoyama T, Gonzalez FJ,
et al. Human livermicrosomal diazepam metabolism using cDNA expressed
cytochrome P450s:role of CYP2B6, 2C19 and the 3A subfamily.
Xenobiotica1996-26:1155-66.
120. Jung F,Richardson TH, Raucy JL,Johnson EF. Diazepam metabolism
by cDNA-expressedhuman 2C P450s: identification of P4502C18 and
P4502C19 as low K(M)diazepam N-demethylases. Drug Metab Dispos
1997-25:133-9.
121. Patwardhan RV,Yarborough GW, Desmond PV, Johnson RF, Schenker
S, Speeg KVJ.Cimetidine spares the glucuronidation of lorazepam and
oxazepam.Gastroenterology 1980-79:912-6.
122. Ghabrial H,Desmond PV, Watson KJ, Gijsbers AJ, Harman PJ, Breen
KJ, et al. Theeffects of age and chronic liver disease on the elimination
of temazepam. Eur JClin Pharmacol 1986-30:93-7.
123. HealthCanada.Canada’salcohol and other drugs survey. 1995-77:1-6.
124. Lemberger L.Tetrahydrocannabinol metabolism in man. Drug Metab
Dispos 1972-1:461-8.
125. Lemberger L, WeissJL, Watanabe AM, Galanter IM, Wyatt RJ, Cardon
PV. Delta-9-tetrahydrocannabinol.Temporal correlation of the psychologic
effects and bloodlevels after various routes of administration. N
Engl J Med1972-30:685-8.
126. Bornheim LM,Lasker JM, Raucy JL. Human hepatic microsomal metabolism
of delta1-tetrahydrocannabinol. Drug Metab Dispos 1992-20:
241-6.
127. Watanabe K,Matsunaga T, Yamamoto I, Funae Y, Yoshimura H. Involvement
of CYP2C in themetabolism of cannabinoids by human hepatic
microsomes from anold woman. Biol Pharm Bull 1995-18:1138;
41.
128. Kosel BW, AweekaFT, Benowitz NL, Shade SB, Hilton JF, Lizak PS,
et al. The effects ofcannabinoids on the pharmacokinetics of indinavir
and nelfinavir. AIDS2002-16:543-50.
129. McDowell JA,Chittick GE, Pilati-Stevens C, Edwards KD, Stein DS.
Pharmacokineticinteraction of abacavir (1592U89) and ethanol in human
immunodeficiencyvirus–infected adults. Antimicrob Agents
Chemother2000-44:1686-90.
1612 The Annals ofPharmacotherapy 2002 October, Volume36 theannals.com
T Antoniou and AL Tseng
Recreational Drug–Antiretroviral Agent Interactions
The Annals of Pharmacotherapy 2002 October, Volume 36 1613 theannals.com
130. Tanaka E, MisawaS. Pharmacokinetic interactions between acute alcohol
ingestion and singledoses of benzodiazepines, and tricyclic and
tetracyclicantidepressants — an update. J Clin Pharm Ther 1998-23:
331-6.
131. Klotz U, AmmonE. Clinical and toxicological consequences of the inductive
potential of ethanol.Eur J Clin Pharmacol 1998-54:7-12.
132. Kostrubsky VE,Strom SC, Wood SG, Wrighton SA, Sinclair PR, Sinclair
JF. Ethanol andisopentanol increase CYP3A and CYP2E in primary
cultures of humanhepatocytes. Arch Biochem Biophys
1995-322:516-20.
133. Hsu A, Bertz R,Granneman GR. Assessing ritonavirdose effect on the
pharmacokineticparameters of protease inhibitors (abstract 3.3). Presented
at: 2nd InternationalWorkshop on Clinical Pharmacology of
HIV Therapy,Noordwijk, theNetherlands,April 2– 4, 2001.
134. Degen O,Kurowski M, Van Lunzen J, Schewe CK, Stellbrink H. Amprenavir
and ritonavir:intraindividual comparison of different doses
and influence ofconcomitant NNRTI on steady-state pharmacokinetics
in HIV-infectedpatients (abstract 739). Presented at: 8th Conference on
Retroviruses andOpportunistic Infections,Chicago,February 4–8,
2001:267.
